Monte Rosa Therapeutics, Inc. announced that Owen Wallace, Ph.D., the Company?s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK-based biotechnology company. Dr. Wallace will serve as a scientific advisor to Monte Rosa, including as a member of its Scientific Advisory Board (SAB).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.09 USD | +2.25% | +2.25% | -27.61% |
May. 30 | Monte Rosa Therapeutics Names Three Insiders to Leadership Team | MT |
May. 30 | Monte Rosa Therapeutics, Inc. Announces Executive Promotions | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.61% | 250M | |
+55.70% | 59.34B | |
+41.08% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+25.85% | 12.28B | |
+2.72% | 12.49B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics, Inc. Announces Departure of Owen Wallace as Chief Scientific Officer and Transition to Member of its Scientific Advisory Board